Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

Draft guidance: 3

Draft guidance (online commenting)

Appeal

Appeal letter - Eli Lilly : Appeal letter (MSWord 86 KB)

Scrutiny letter - Eli Lilly : Scrutiny letter (MSWord 113 KB)

Response to scrutiny letter - Eli Lilly : Response to scrutiny letter (MSWord 75 KB)

Final scrutiny letter : Final scrutiny letter (MSWord 77 KB)

Final draft guidance

Final draft guidance (PDF 384 KB)

Committee papers (PDF 2 MB)

Public committee slides (PDF 642 KB)

Draft guidance: 2

Draft guidance (downloadable version) (PDF 399 KB)

Draft guidance (online commenting)

Committee papers (PDF 3.4 MB)

Public committee slides (PDF 605 KB)

Draft guidance

Draft guidance (downloadable version) (PDF 339 KB)

Draft consultation document (online commenting)

Committee papers (PDF 8.66 MB)

Public committee slides (PDF 1.32 MB)

Final scope (PDF 200 KB)

Final stakeholder list (PDF 169 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 481 KB)

Note

Note

Note

Note

Draft matrix post referral (PDF 164 KB)